NURIX THERAPEUTICS, INC. (NRIX) Financial Analysis — Fisclear

Valuation

Pharmaceutical Preparations

Live · Yahoo Finance

Price

$23.74

52-Week Range

$8.20$23.74 now$25.09

Decision Context

Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.

Based on filing period ending May 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

NRIX vs

Macro Context

Fed Funds Rate

3.63%

Accommodative

10-Year Treasury

4.47%

2026-06-01

Unemployment

4.2%

Near full employment

CPI Index

332.6

2026-06-01

M2 Money Supply

$23.1T

2026-05-01

The Federal Funds rate stands at 3.63% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.47%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 102.6; M2 money supply is $23.1T; CPI index stands at 332.6.

SWOT Analysis — NRIX

Inflationary Boom

Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.

✦

Strengths

Revenue: $77.0M (+99.3% YoY) — Revenue grew 99% — the company sold more goods or services than the prior year.

◈

Weaknesses

Operating Cash Flow: -$249.5M (-44.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$264.5M (-36.6% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-3.05 (-5.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
R&D spending is 412% of revenue — heavy investment in future growth, but also a drag on current profitability.

◎

Opportunities

Total Assets: $688.1M (+2.8% YoY) — Total assets grew 3% — the company's resource base expanded.

⚠

Threats

Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.

Financial Charts

Revenue vs Net Income

Margin Trend

Operating Cash Flow

Year-over-Year Changes

Revenue

$77.0M

was $38.6M

+99.3%

Revenue grew 99% — the company sold more goods or services than the prior year.

Operating Cash Flow

-$249.5M

was -$172.6M

−44.5%

Negative operating cash flow — the business consumed more cash than it produced from operations.

Net Income

-$264.5M

was -$193.6M

−36.6%

The company posted a net loss — total expenses exceeded total revenue.

EPS (Diluted)

$-3.05

was $-2.88

−5.9%

Negative EPS — the company recorded a loss on a per-share basis.

Total Assets

$688.1M

was $669.3M

+2.8%

Total assets grew 3% — the company's resource base expanded.

Risk Flags

2 high · 0 medium · 1 low

⚠ High
Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.
⚠ High
Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.
○ Low
R&D spending is 412% of revenue — heavy investment in future growth, but also a drag on current profitability.